Related references
Note: Only part of the references are listed.Recognition of and treatment recommendations for oligometastatic disease in multidisciplinary tumor boards
Sebastian M. Christ et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2023)
An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer
Saad Sheikh et al.
RADIOTHERAPY AND ONCOLOGY (2022)
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET) – Extended Long-Term Outcomes
Stephen Harrow et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers
C.J. Tsai et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Imaging-Based Prevalence of Oligometastatic Disease: A Single-Center Cross-Sectional Study
Sebastian M. Christ et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Distant Metastasis Velocity as a Novel Prognostic Score for Overall Survival After Disease Progression Following Stereotactic Body Radiation Therapy for Oligometastatic Disease
Jonas Willmann et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).
Steven J. Chmura et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease
Alban Macagno et al.
CURRENT ONCOLOGY (2022)
A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions
George J. Li et al.
ANNALS OF PALLIATIVE MEDICINE (2021)
Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease
Yilin Cao et al.
CANCER MEDICINE (2021)
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Yolande Lievens et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
Daniel R. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis
Sean P. Pitroda et al.
NATURE COMMUNICATIONS (2018)
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
Theo Ruers et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
Theo Ruers et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Daniel R. Gomez et al.
LANCET ONCOLOGY (2016)
ANALYSIS OF PATIENTS WITH OLIGOMETASTASES UNDERGOING TWO OR MORE CURATIVE-INTENT STEREOTACTIC RADIOTHERAPY COURSES
Michael T. Milano et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Share Paper
